The hypoxic response of tumors is dependent on their microenvironment

Cancer Cell

Volumn 4, Issue 2, 2003, Pages 133-146

  Blouw, Barbara ^a   Song, Hanqiu ^b   Tihan, Tarik ^c   Bosze, Jenel ^a   Ferrara, Napoleone ^d   Gerber, Hans Peter ^d   Johnson, Randall S ^a   Bergers, Gabriele ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; BRAIN METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CELL GROWTH; CELL TYPE; CONTROLLED STUDY; GENE DELETION; GENETIC ENGINEERING; HYPOXIC CELL; INTERMETHOD COMPARISON; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TISSUE REACTION;

ANIMALIA; MURINAE;

EID: 0041382820     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00194-6     Document Type: Article

References (43)

1. Abdulmalek K., Ashur F., Ezer N., Ye F., Magder S., Hussain S.N. Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 281:2001;L582-L590.
2. Brat D.J., Castellano-Sanchez A., Kaur B., Van Meir E.G. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9:2002;24-36.
3. Brat D.J., Kaur B., Van Meir E.G. Genetic modulation of hypoxia induced gene expression and angiogenesis. relevance to brain tumors Front. Biosci. 8:2003;D100-D116.
4. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P.et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
5. Chaudhry I.H., O'Donovan D.G., Brenchley P.E., Reid H., Roberts I.S. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 39:2001;409-415.
6. Cuenca R.E., Takita H., Bankert R. Orthotopic engraftment of human lung tumours in SCID mice for the study of metastasis. Surg. Oncol. 5:1996;85-91.
7. Ding H., Roncari L., Shannon P., Wu X., Lau N., Karaskova J., Gutmann D.H., Squire J.A., Nagy A., Guha A. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 61:2001;3826-3836.
8. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors. implications for antiangiogenic tumor therapies Cancer Res. 60:2000;1388-1393.
9. Feldkamp M.M., Lau N., Rak J., Kerbel R.S., Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer. 81:1999;118-124.
10. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9:2003;669-676.
11. Folkman J. Tumor angiogenesis. Robert C., Bast Jr. Cancer Medicine. 2000;BC Decker, Hamilton, Ontario.
12. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F., Aguet M., Ferrara N. VEGF is required for growth and survival in neonatal mice. Development. 126:1999;1149-1159.
13. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:2003;359-369.
14. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59:1999;1592-1598.
15. Guha A., Feldkamp M.M., Lau N., Boss G., Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 15:1997;2755-2765.
16. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 277:1997;48-50.
17. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy. microvessel density, what it does and doesn't tell us J. Natl. Cancer Inst. 94:2002;883-893.
18. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998. a.
19. Holash J., Wiegand S.J., Yancopoulos G.D. New model of tumor angiogenesis. dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF Oncogene. 18:1999;5356-5362. b.
20. Holland E.C. Glioblastoma multiforme. the terminator Proc. Natl. Acad. Sci. USA. 97:2000;6242-6244.
21. Huang P., Allam A., Taghian A., Freeman J., Duffy M., Suit H.D. Growth and metastatic behavior of five human glioblastomas compared with nine other histological types of human tumor xenografts in SCID mice. J. Neurosurg. 83:1995;308-315.
22. Inoue M., Hager J.H., Ferrara N., Gerber H.P., Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 1:2002;193-202.
23. Louis D.N., Holland E.C., Cairncross J.G. Glioma classification. a molecular reappraisal Am. J. Pathol. 159:2001;779-786.
24. MacDonald T.J., Taga T., Shimada H., Tabrizi P., Zlokovic B.V., Cheresh D.A., Laug W.E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 48:2001;151-157.
25. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N.et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60.
26. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA. 94:1997;8104-8109.
27. Miyoshi T., Kondo K., Ishikura H., Kinoshita H., Matsumori Y., Monden Y. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res. 20:2000;161-163.
28. Naik P., Karrim J., Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis. down-modulation contributes to progression from angiogenic progenitors Genes Dev. 10:1996;2105-2116.
29. Ozawa T., Wang J., Hu L.J., Lamborn K.R., Bollen A.W., Deen D.F. Characterization of human glioblastoma xenograft growth in athymic mice. In Vivo. 12:1998;369-374.
30. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L.et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218.
31. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia. role of the HIF system Nat. Med. 9:2003;677-684.
32. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., Shuman M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2:2000;306-314.
33. Ryan H.E., Lo J., Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
34. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015.
35. Semenza G.L. HIF-1 and tumor progression. pathophysiology and therapeutics Trends Mol. Med. 8:2002;S62-S67. a.
36. Semenza G.L. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med. 41:2002;79-83. b.
37. Taillandier L., Antunes L., Angioi-Duprez K.S. Models for neuro-oncological preclinical studies. solid orthotopic and heterotopic grafts of human gliomas into nude mice J. Neurosci. Methods. 125:2003;147-157.
38. Tsuzuki Y., Fukumura D., Oosthuyse B., Koike C., Carmeliet P., Jain R.K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α→ hypoxia response element→ VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60:2000;6248-6252.
39. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., Wenger R.H. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene. 22:2003;3213-3220.
40. Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:2003;219-231.
41. Xiao A., Wu H., Pandolfi P.P., Louis D.N., Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1:2002;157-168.
42. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 407:2000;242-248.
43. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1α in brain tumors. association with angiogenesis, invasion, and progression Cancer. 88:2000;2606-2618.